Results 91 to 100 of about 1,228 (155)
Journal of Evidence-Based Medicine, Volume 17, Issue 4, Page 729-739, December 2024.Abstract Objective To summarize the evidence on the efficacy and safety of vancomycin compared with those of alternative treatments in adult patients with methicillin‐resistant Staphylococcus aureus (MRSA) infection. Methods PubMed, Embase, and Web of Science were searched up to December 15, 2023, for systematic reviews and meta‐analyses comparing ...
Sujata Purja +4 more
wiley +1 more source
Smart Molecules, Volume 4, Issue 3, September 2026.No abstract is available for this article.
wiley +1 more source
Searching for “Greener” Bioequivalents of CF3 to Lower its Environmental Impact
Chemistry – A European Journal, Volume 30, Issue 50, September 5, 2024.Considering concerns on the negative environmental effects of CF3 containing compounds, we searched for “greener” alternatives. We found −I as the best alternative since it is equivalent in all aspects studied, size, electronic and lipophilic, followed by −F, ‐cyclo‐Pr, −2‐oxetyl, −SF5 and −SCH3. We suggest using these functionalities as an alternative
Marco Minneci +2 more
wiley +1 more source
Brazilian Journal of Infectious DiseasesIntroduction/Objective: Indiscriminate use of quinolones, especially after the COVID-19 pandemic, has contributed to increased bacterial resistance, including methicillin-resistant Staphylococcus aureus (MRSA).
Stefânia Bazanelli Prebianchi +5 more
doaj +1 more source
Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates. [PDF]
, 2014 Biofilm-related infections remain a scourge. In an in vitro model of biofilms using Staphylococcus aureus reference strains, delafloxacin and daptomycin were found to be the most active among the antibiotics from 8 different pharmacological classes (J ...
Hallin, Marie +5 more
core +1 more source
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
Microorganisms, 2019 Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel
Despoina Koulenti +7 more
doaj +1 more source
A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP) [PDF]
, 2019 The clinical and economic burden of community-acquired bacterial pneumonia (CABP) is significant and is anticipated to increase as the population ages and pathogens become more resistant.
Cheng, Chun-Yen +8 more
core +1 more source
Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, New York
Clinical Infectious Diseases, 2019 Abstract Delafloxacin is an option for infections due to methicillin-resistant Staphylococcus aureus. In 2017, 22% of isolates from 7 hospitals in Brooklyn, New York, were nonsusceptible to delafloxacin. Isolates belonging to ST105, a strain associated with healthcare-related infections, predominated.
Alejandro, Iregui +4 more
openaire +2 more sources
OBJECTIVES: We assessed the in vitro activity of delafloxacin and the synergy between cefotaxime and delafloxacin among cefotaxime non-susceptible invasive isolates of Streptococcus pneumoniae (CNSSP).
Pérez, M +9 more
core +1 more source
AntibioticsHigh-level delafloxacin-resistant (H-L DLX-R) Staphylococcus aureus isolates (minimum inhibitory concentration ≥1 mg/L) associated with mutations affecting position 84 of ParC have emerged. We aimed to elucidate the role of these mutations as a mechanism
Silvia Bolaños +5 more
doaj +1 more source